藤芪通络颗粒治疗2型糖尿病下肢血管病变的疗效及对患者血清Vaspin、RBP4水平的影响

Efficacy of Tengqi Tongluo Granule in Treating Type 2 Diabetes with Lower Extremity Vascular Disease and Its Influence on Serum Vaspin and RBP4 Levels

  • 摘要: 目的 观察藤芪通络颗粒治疗2型糖尿病下肢血管病变气虚血瘀证的疗效,及对血清Vaspin、RBP4水平的影响。方法 采用随机、平行对照临床研究设计,选择2型糖尿病下肢血管病变(DLEAD)中医辨证气虚血瘀证者2组各30例。治疗组在基础治疗(降糖、降压、调脂、抗血小板聚集)上加用藤芪通络颗粒口服,对照组仅予基础治疗,连续服药12周。观察治疗后2组患者糖脂代谢、血压、踝肱指数(ABI)、足背动脉血流量以及血清腹腔脂肪型丝氨酸蛋白酶抑制剂(Vaspin)、视黄醇结合蛋白4(RBP4)水平。结果 治疗后2组血糖(FBG、PBG、HbA1c)含量均下降(P<0.05~0.01),但组间差异无统计学意义(P>0.05);治疗组血脂(TC、TG、LDL-C)较治疗前下降(P<0.05~0.01),HDL-C水平有所升高(P>0.05),且治疗组优于对照组(P<0.05);2组ABI及足背动脉血流量均升高、Vaspin水平上升、RBP4水平下降(P<0.05~0.01),治疗组优于对照组(P<0.05);2组均能改善中医证候积分(P<0.05),治疗组在改善肢体疼痛、倦怠乏力优于对照组(P<0.05);临床疗效治疗组优于对照组( P<0.05)。结论 藤芪通络颗粒可以升高患者血清Vaspin水平,降低RBP4水平,一定程度上改善脂代谢,提高ABI及足背动脉血流量,改善DLEAD患者下肢缺血症状,提高临床疗效。

     

    Abstract: OBJECTIVE To observe the curative effect of Tengqi Tongluo granule in treating type 2 diabetes with lower extremity vascular disease with qi deficiency and blood stasis syndrome, and its effect on serum Vaspin and RBP4 levels. METHODS A randomized, parallel controlled clinical study design was adopted. According to traditional Chinese medicine syndrome differentiation of qi deficiency and blood stasis, patients with type 2 diabetic lower extremity vascular disease (DLEAD) were selected and divided into two groups with 30 cases each. The treatment group was treated with Tengqi Tongluo granule orally in addition to the basic treatment (hypoglycemic treatment, antihypertensive treatment, lipid regulation, and anti-platelet aggregation), while the control group received only the basic treatment. The course lasted for 12 weeks. After treatment, the glucose, lipid metabolism, blood pressure, ankle-brachial index (ABI), dorsal arterial volume, visceraladiposetissue-derived serine protease inhibitor (Vaspin) and retinol binding protein 4 (RBP4) levels were observed in both groups. RESULTS After treatment, the blood glucose (FBG, PBG, HbAlc) levels of both groups decreased (P<0.05, P<0.01), but the difference between the groups was not statistically significant (P>0.05). Blood lipids (TC, TG, LDL-C) in the treatment group decreased compared with those before treatment (P<0.05, P<0.01), HDL-C increased (P>0.05), and the effect in the treatment group was better than that of the control group (P<0.05). The ABI, dorsal arterial volume and Vaspin level of the two groups increased, while RBP4 level decreased (P<0.05, P<0.01), and the effects in the treatment group were better than those of the control group (P<0.05). The clinical efficacy in the treatment group was better than that of the control group (P<0.05). CONCLUSION Tengqi Tongluo granule can increase the serum Vaspin level, reduce RBP4 level, improve lipid metabolism, increase ABI and dorsal arterial volume, improve lower limb ischemia symptoms of DLEAD patients, and improve clinical efficacy.

     

/

返回文章
返回